908 Devices (NASDAQ:MASS) SVP Sells $38,102.60 in Stock

908 Devices Inc. (NASDAQ:MASS) SVP Kevin Mccallion sold 5,420 shares of the business’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $7.03, for a total value of $38,102.60. Following the sale, the senior vice president owned 44,925 shares of the company’s stock, valued at approximately $315,822.75. The trade was a 10.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

908 Devices Price Performance

MASS stock opened at $7.14 on Monday. The company has a market cap of $266.89 million, a P/E ratio of 12.98 and a beta of 0.54. 908 Devices Inc. has a twelve month low of $3.79 and a twelve month high of $9.34. The business has a fifty day moving average of $6.47 and a 200-day moving average of $6.66.

908 Devices (NASDAQ:MASS) last released its earnings results on Tuesday, March 3rd. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. The company had revenue of $17.38 million during the quarter, compared to the consensus estimate of $16.19 million. 908 Devices had a negative return on equity of 14.99% and a net margin of 34.68%. As a group, equities research analysts anticipate that 908 Devices Inc. will post -1.99 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Wall Street Zen upgraded 908 Devices from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 908 Devices in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $12.00.

Key Headlines Impacting 908 Devices

Here are the key news stories impacting 908 Devices this week:

• Neutral Sentiment: SVP Kevin J. McCallion sold 18,580 shares on April 8 at an average $7.05 (proceeds $130,989). The sale was executed under a Rule 10b5‑1 plan and left him with 44,925 shares. Form 4
• Neutral Sentiment: SVP Kevin J. McCallion sold an additional 5,420 shares on April 9 at an average $7.03 (proceeds ~$38.1k), also under a 10b5‑1 plan. He still holds 44,925 shares. Form 4
• Neutral Sentiment: Director Christopher D. Brown sold 17,578 shares on April 10 at $7.07 (proceeds ~$124.3k), under a 10b5‑1 plan; he remains a large holder (~945,559 shares). Form 4
• Neutral Sentiment: Director Christopher D. Brown sold 7,392 shares on April 9 at $7.04 (proceeds ~$52.0k), and 15,030 shares on April 8 at $7.05 (proceeds ~$106.0k); all under a 10b5‑1 plan. Form 4
• Neutral Sentiment: Reported short interest shows 0 shares (as of April 10), implying no measurable short pressure; the short‑interest ratio is effectively 0.0 days based on average volume. Source data flagged anomalous/NaN changes.
• Negative Sentiment: Combined impact: insiders sold ~64,000 shares this week for roughly $450k in proceeds. Even though sales were via 10b5‑1 plans (which mutes informational content), the concentrated volume of insider selling can create near‑term downward pressure or raise investor questions about insider liquidity needs.

Institutional Investors Weigh In On 908 Devices

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers increased its holdings in 908 Devices by 5.5% in the second quarter. Rhumbline Advisers now owns 36,416 shares of the company’s stock valued at $260,000 after purchasing an additional 1,894 shares during the last quarter. Graham Capital Management L.P. increased its holdings in 908 Devices by 12.9% in the fourth quarter. Graham Capital Management L.P. now owns 20,787 shares of the company’s stock valued at $109,000 after purchasing an additional 2,374 shares during the last quarter. Farther Finance Advisors LLC bought a new stake in 908 Devices in the third quarter valued at about $28,000. Cresset Asset Management LLC increased its holdings in 908 Devices by 37.1% in the third quarter. Cresset Asset Management LLC now owns 16,100 shares of the company’s stock valued at $141,000 after purchasing an additional 4,355 shares during the last quarter. Finally, Barclays PLC increased its holdings in 908 Devices by 15.4% in the fourth quarter. Barclays PLC now owns 44,528 shares of the company’s stock valued at $234,000 after purchasing an additional 5,943 shares during the last quarter. Institutional investors own 88.06% of the company’s stock.

908 Devices Company Profile

908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company’s core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.